Global Leading Market Research Publisher QYResearch announces the release of its latest report “Drug-Induced Dyskinesia – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Drug-Induced Dyskinesia market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Drug-Induced Dyskinesia was estimated to be worth US$ 389 million in 2025 and is projected to reach US$ 539 million, growing at a CAGR of 4.9% from 2026 to 2032.
Drug-Induced Dyskinesia refers to involuntary, abnormal movements of the face, limbs, or body caused as a side effect of certain medications, most commonly those that affect dopamine pathways such as antipsychotics or drugs used in Parkinson’s disease. These movements can include tremors, tics, twisting motions, or repetitive movements, and may be temporary or persistent depending on the drug exposure and patient susceptibility.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095625/drug-induced-dyskinesia
1. Industry Pain Points and the Shift Toward VMAT2 Inhibition
Tardive dyskinesia (TD) affects 20-30% of patients on long-term antipsychotic medications (schizophrenia, bipolar disorder), causing involuntary orofacial and limb movements. These movements are stigmatizing, distressing, and often irreversible. Traditional treatments (dopamine-depleting medications, benzodiazepines) have limited efficacy and significant side effects. Drug-induced dyskinesia treatments have shifted toward VMAT2 inhibitors (valbenazine, deutetrabenazine), which reduce presynaptic dopamine release. For psychiatrists, neurologists, and patients, tardive dyskinesia treatment with VMAT2 inhibitors offers significant symptom reduction (40-60% improvement) with favorable safety profiles.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global drug-induced dyskinesia market was valued at US$ 389 million in 2025 and is projected to reach US$ 539 million by 2032, growing at a CAGR of 4.9%. Market growth is driven by three factors: increasing long-term antipsychotic use (schizophrenia, bipolar disorder, major depressive disorder), FDA approvals of VMAT2 inhibitors (valbenazine in 2017, deutetrabenazine in 2017), and expanded labeling for tardive dyskinesia (previously only Huntington’s chorea).
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- Generic VMAT2 inhibitors: Valbenazine (Ingrezza) patent expiration (2026) will enable generic entry, reducing price by 50-70%. Generic segment expected to capture 30% market share by 2028.
- Expanded prescribing: VMAT2 inhibitor prescriptions for tardive dyskinesia grew 15% year-over-year (US claims data), driven by increased awareness and telepsychiatry.
- Pediatric indication: Clinical trials for VMAT2 inhibitors in pediatric antipsychotic-induced movement disorders (12-17 years) ongoing, potential label expansion by 2027-2028.
- Combination therapy: VMAT2 inhibitors + deutetrabenazine (reduced dose) for refractory tardive dyskinesia in Phase 2 trials, aiming for improved efficacy with lower side effects.
4. Competitive Landscape and Key Suppliers
The market includes VMAT2 inhibitor innovators and generic manufacturers:
- Neurocrine Bioscience (US – Ingrezza, valbenazine), Teva Pharmaceuticals (Israel – Austedo, deutetrabenazine), Sun Pharmaceutical Industries (India – generic deutetrabenazine), SteriMax (Canada), Lannett (US), Adamas Pharmaceuticals (US – Gocovri, amantadine for Parkinson’s dyskinesia), Sanis (generic), AbbVie (US – legacy dopamine-depleting medications).
Competition centers on three axes: efficacy (AIMS score reduction), dosing convenience (once-daily vs. twice-daily), and side effect profile (depression, suicidality, akathisia).
5. Segment-by-Segment Analysis: Type and Application
By Drug Class
- VMAT2 Inhibitors: Largest and fastest-growing segment (~70% of market). Valbenazine (Ingrezza), deutetrabenazine (Austedo). Once-daily dosing, 40-60% AIMS score reduction. CAGR 6%.
- Dopamine-Depleting Medications: (~20% of market). Tetrabenazine (Xenazine), reserpine. Older agents, more side effects (depression, Parkinsonism). Declining use.
- Other (amantadine, benzodiazepines, clozapine): ~10% of market.
By End User
- Hospitals: Largest segment (~60% of market). Psychiatric hospitals, neurology clinics, movement disorder centers.
- Clinic: (~30% of market). Outpatient psychiatry, neurology private practice.
- Other: Long-term care facilities, home health. ~10% of market.
User case – Tardive dyskinesia (valbenazine) : A 55-year-old patient with schizophrenia (20+ years antipsychotics) developed severe orofacial tardive dyskinesia (AIMS score 24). Valbenazine (Ingrezza, 80 mg/day) initiated. After 12 weeks, AIMS score reduced to 12 (50% improvement). Patient reported improved social functioning and reduced stigma. No significant side effects (mild somnolence). Treatment continued for 24+ months (sustained response).
6. Exclusive Insight: VMAT2 Inhibitor Comparison
| Parameter | Valbenazine (Ingrezza) | Deutetrabenazine (Austedo) | Tetrabenazine (Xenazine) |
|---|---|---|---|
| Mechanism | VMAT2 inhibitor (reversible) | VMAT2 inhibitor (reversible) | VMAT2 inhibitor (reversible) |
| Approval | Tardive dyskinesia (2017) | Tardive dyskinesia (2017), Huntington’s chorea (2008) | Huntington’s chorea (2008) |
| Dosing | Once daily (80 mg) | Twice daily (12-48 mg) | Twice-thrice daily (25-100 mg) |
| Efficacy (AIMS reduction) | 3.0-3.2 points (placebo-subtracted) | 2.5-3.0 points | N/A (Huntington’s) |
| Depression warning | Yes (boxed warning) | Yes (boxed warning) | Yes (boxed warning) |
| Somnolence incidence | 5-10% | 10-15% | 15-20% |
| Drug interactions | Strong CYP2D6 inhibitors | Strong CYP2D6 inhibitors | Strong CYP2D6 inhibitors |
| Cost per month (US) | US$ 5,000-6,000 | US$ 4,000-5,000 | US$ 2,000-3,000 (generic) |
| Generic availability | 2026 (patent expiry) | 2025-2026 (Teva, Sun) | Available |
Technical challenge: Depression and suicidality risk with VMAT2 inhibitors (boxed warning). Contraindicated in patients with active suicidal ideation or untreated depression. Requires baseline and ongoing depression screening. Valbenazine and deutetrabenazine have lower depression risk than tetrabenazine (2-3% vs. 10-15%).
User case – Depression screening prior to VMAT2 inhibitor: A patient with schizophrenia and tardive dyskinesia screened positive for depression (PHQ-9 score 15) before VMAT2 inhibitor initiation. Depression treated first (SSRI). After 8 weeks, PHQ-9 score improved to 6. VMAT2 inhibitor started with close monitoring. No worsening of depression.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (60% share, CAGR 5%). US (Neurocrine, Teva, Adamas, Lannett). Strong VMAT2 inhibitor adoption (Ingrezza, Austedo), telepsychiatry expansion.
- Europe: Second-largest (20% share, CAGR 4.5%). Limited VMAT2 inhibitor reimbursement, slower adoption.
- Asia-Pacific: Fastest-growing region (CAGR 5.5%). Japan, China, India. Increasing antipsychotic use, emerging awareness of tardive dyskinesia.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The drug-induced dyskinesia market is positioned for steady growth through 2032, driven by long-term antipsychotic use, VMAT2 inhibitor approvals, and generic entry. Stakeholders—from pharmaceutical companies to psychiatrists—should prioritize VMAT2 inhibitors for efficacy and tolerability, depression screening for safety, and once-daily dosing for adherence. By enabling tardive dyskinesia treatment, VMAT2 inhibitors improve quality of life for patients with antipsychotic-induced movement disorders.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
